Co-Founder and CEO at Snipr Biome Christian Grøndahl is very excited about the fact that the US Food and Drug Administration (FDA) recently awarded its special fast-track designation to the biotech company’s candidate, SNIPR001.
”It’s not given out very often, and receiving such special treatment from the FDA is very favorable. It is in part an acknowledgement of the great need for the drug, but also that our experimental drug looks promising,” Grøndahl tells MedWatch.
More from MedWatch
In 2015, Genmab partnered with relatively unknown biotech firm Biontech. Reflecting on how far Genmab has come since, CEO Jan van de Winkel is still confident that partnerships, rather than acquisitions, are the way forward. If it had acquired Biontech at the time, the CEO speculates Genmab may have put a stop to other activities – including the Covid-19 vaccine efforts that went on to save millions of lives. This and fairness are worth remembering as biotech firms are increasingly strapped for cash, van de Winkel reflects.